XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Revenue - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 23, 2021
Dec. 07, 2020
May 16, 2019
Nov. 14, 2017
Dec. 31, 2020
Jun. 30, 2019
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2018
Dec. 31, 2021
Nov. 06, 2018
Disaggregation Of Revenue [Line Items]                            
Milestone payments received                   $ 2,800,000        
Transaction price recorded in liabilities             $ 2,500,000     2,500,000        
Collaboration revenue             26,000   $ 2,739,000 1,026,000 $ 4,291,000      
Short-term research and development contract liability             0     0     $ 645,000  
Milestone payment associated with contract liability $ 3,000,000 $ 1,250,000 $ 2,500,000                      
Prepaid expenses and other short-term assets             2,142,000     2,142,000     955,000  
Other long-term assets             134,000     134,000     140,000  
Collaboration Agreement with Merck | Merck                            
Disaggregation Of Revenue [Line Items]                            
Up Front Non Refundable Payment       $ 2,500,000                    
Milestone payments received       $ 2,500,000                    
Collaboration revenue             0   704,000 0 1,469,000      
Collaboration Agreement with LG Chem Life Sciences | LG Chem Life Sciences                            
Disaggregation Of Revenue [Line Items]                            
Milestone payments received 3,000,000 1,250,000 2,500,000         $ 6,750,000            
Collaboration revenue             26,000   $ 2,035,000 1,026,000 $ 2,823,000      
Short-term research and development contract liability                         645,000  
Equity investment nonrefundable upfront cash payment                           $ 5,000,000.0
Equity investment for research collaboration agreement                           5,000,000.0
Milestone payment associated with contract liability 3,000,000 1,250,000 2,500,000                      
Income tax expense $ 495,000 $ 206,250 $ 412,500                      
Collaboration Agreement with LG Chem Life Sciences | LG Chem Life Sciences | Maximum                            
Disaggregation Of Revenue [Line Items]                            
Additional amount receivable research development regulatory and sales milestones                           $ 400,000,000.0
Collaboration Agreement with LG Chem Life Sciences | Einstein                            
Disaggregation Of Revenue [Line Items]                            
Prepaid expenses and other short-term assets             $ 0     0        
Einstein License And Service Agreement | Einstein                            
Disaggregation Of Revenue [Line Items]                            
Cost Of Goods And Services Sold         $ 157,000 $ 313,000       $ 908,000   $ 438,000    
Prepaid expenses and other short-term assets                         $ 80,000